Source: MGC Pharmaceuticals
Market Herald logo


Be the first with the news that moves the market
  • MGC Pharma (MXC) recruits its first patient for the phase three CimetrA clinical trial in Israel
  • MXC is testing the treatment’s safety and efficacy on patients with moderate forms of COVID-19
  • A total of 252 patients will take place in the trial which will provide additional data for CimetrA’s Investigational Medicinal Product (IMP) status
  • MXC says the data from the trial should meet the European Medical Agency’s qualification as well
  • Company shares are trading up 5.26 per cent at 4 cents each

MGC Pharma (MXC) has recruited its first patient for the phase three CimetrA clinical trial at the Rambam Medical Centre in Israel.

The trial will test the treatment’s safety and efficacy on hospitalised patients with moderate forms of COVID-19.

It’ll also test how the treatment works when combined with a new drug carrier, which should deliver natural ingredients more effectively in higher concentrations.

A total of 252 patients will take place in the study in Israel and the additional data from the trial will be used to advance CimetrA’s Investigational Medicinal Product (IMP) status.

The treatment has already completed IMP production, validation, and ethics committee approval and MXC wants the data from this trial to meet the European Medicines Agency’s (EMA) qualification.

Explaining the significance of the first patient, MGC Pharma co-founder and Managing Director Roby Zomer said it meant the trial could now commence.

Mr Zomer added the company was excited to get a better understanding of the valid claims that can be made for CimetrA.

“The commencement of the phase three clinical trial is a milestone achievement for both MGC Pharma and the medicinal cannabis industry,” Mr Zomer said.

“Testing CimetrATM as an IMP will have great implications for those suffering with COVID-19 and ensure the risk of healthcare systems becoming overwhelmed is minimised.”

MGC Pharma shares were trading up 5.26 per cent at 4 cents each towards the close of market on Tuesday.

MXC by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.